|
|
Article: CepTor Eyeing Ferring's SOD Drug For Neonatal Application.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
CepTor Corp. is hoping to breathe new life into a product aimed at preventing chronic respiratory morbidity in premature newborns.
The Hunt Valley, Md.-based firm signed a letter of intent to purchase recombinant human copper zinc superoxide dismutase (SOD) from Ferring International SA.
The deal is contingent upon reaching an agreement with the FDA regarding the "clinically relevant" endpoints for a Phase IIb trial, said Bill Pursley, chairman and CEO of CepTor.
Pending that agreement, the company would make an exclusive option payment to Lausanne, Switzerland-based Ferring, which will "provide us with a significant ...